Sirtex Medical Limited

ASX:SRX ISIN:AU000000SRX1

Sirtex Medical aims to become the world leader in liver cancer treatment products. The company believes the unmet demand for effective treatment of liver cancer provides an opportunity for the application of its products. Futhermore, Sirtex Medical aims to apply its micro-sphere technology to other diseases where the company's intellectual property can provide market opportunities. 
 

News

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 12000

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

Sirtex Medical (ASX:SRX) Announces New Manufacturing Facility In Singapore To Support Asian Growth

🕔10/27/2009 4:03:41 PM 11748

Sirtex Medical (ASX:SRX)(PINK:SXMDF) has delivered record revenues and profit. Highlights include; total product revenue for the year ended 30 June 2009 was A$65.6 million, up 72 per cent on the previous year. Net profit after tax of A$18.2 million was up 1,406 per cent on the last year. SIR-Spheres microspheres dose sales were up 42 per cent to 3,658 doses.

Read Full Article

Biota Holdings Limited (ASX:BTA) Appoints Mr Richard Hill As Director

🕔11/28/2008 3:50:41 PM 8531

Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.

Read Full Article

Sirtex Medical Limited ASX: SRX - Sirtex Medical to Sponsor FAST Clinical Trial - Dr Gilman Wong, CEO

🕔4/13/2007 11:43:00 AM 5659

Sirtex Medical Limited (ASX: SRX) - Sirtex Medical to Sponsor FAST Clinical Trial - Dr Gilman Wong, CEO; Boardroomradio is pleased to announce that Sirtex Medical Limited (ASX: SRX) has published an audio file.

Read Full Article
###

5,673 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 26) (Since Published: 5673) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Pharmaceutical 

More News Results

  • 2024/03/28: 2023 Corporate Governance Statement and Appendix 4G*
  • 2024/03/28: Sierra Rutile 2023 Annual Report*
  • 2024/03/28: Take No Action on Inadequate Offer*
  • 2024/03/28: Sembehun capex estimate reduced from PFS estimate*
  • 2024/03/27: Update on Section 249D Notice and Director Nominations*
  • 2024/03/26: Replacement Bidders Statement - Market bid*
  • 2024/03/25: Change in substantial holding*
  • 2024/03/22: Notice received under Section 249N of the Corporations Act*
  • 2024/03/22: Change in substantial holding*
  • 2024/03/22: Change in substantial holding*
*refer to company website